# Haptena Therapeutics S.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haptena-therapeutics-s-r-l

- Industry: Healthcare Specialists
- Headquarters: Turin, Italy
- Website: www.haptena.com/
- Total disclosed funding: $3.5M
- Latest round: Seed (Dec 8, 2025)
- Investors on record: 1

## About

Haptena Therapeutics S.r.l., based in Turin, Italy, focuses on developing innovative immunotherapies for genetically defined cancers, particularly KRAS-driven tumors, aiming to enhance treatment efficacy using advanced targeted therapies and immune modulation.Haptena Therapeutics S.r.l. is engaged in the development of immunotherapies aimed at addressing genetically defined cancers. Founded in 2025 in Turin, Italy, the company successfully secured EUR 3 million in Seed funding from Claris Ventures in January 2026. The total amount raised by the company stands at EUR 3 million, following its initial deal.Haptena Therapeutics specializes in developing next-generation immunotherapies tailored for genetically defined cancers, with a primary focus on KRAS-driven tumors. The company integrates the precision of targeted therapies with the transformative potential of immune-based treatments to address the limitations of existing cancer therapies. Their core product offerings aim to enhance treatment efficacy for oncogenes, which are often inadequately addressed by current solutions. By targeting mechanisms of resistance and tumor adaptation, Haptena seeks to deliver innovative treatment options that provide more durable responses for patients facing challenging tumors. The company's products are marketed primarily within the European Union, where they aim to serve healthcare providers, oncologists, and patients grappling with complex cancer diagnoses.Haptena Therapeutics generates revenue through strategic partnerships and collaborations aimed at advancing its proprietary therapies for KRAS-driven cancers. Transactions typically occur through agreements with pharmaceutical companies and research institutions, facilitating the development and potential commercialization of their innovative products. Revenue streams may include milestone payments, licensing fees, and royalties derived from successful product launches and market penetration. The company's flagship offerings are likely to be included in these partnership agreements, enabling the alignment of interests with various stakeholders in the oncology field. By fostering relationships with both biopharmaceutical partners and healthcare providers, Haptena positions itself to capitalize on the growing demand for effective cancer treatments.In January 2026, Haptena Therapeutics S.r.l. raised EUR 3 million in Seed funding from Claris Ventures, which will support the further development of its program and expand its pipeline for tumors. The company plans to introduce upcoming products designed to enhance treatment options by targeting new mechanisms of resistance in cancer therapy. Additionally, Haptena aims to expand its market presence beyond Europe, looking toward potential opportunities in North America and Asia by late 2026.

## Funding rounds

- Seed, Dec 8, 2025, $3.5M — Claris Ventures

## Investors

- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Seed